Innovating medicines
for breast cancer and beyond.
Innovating medicines
for breast cancer and beyond.
Innovating medicines
for breast cancer and beyond.
Pursuing better treatments to help patients feel better, longer.
Bring your passion, join our team and make your mark.
Olema's latest news and recent events.
-
February 4th, 2025 Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
February 3rd, 2025 Olema Oncology to Participate in Upcoming Investor Conferences
-
January 3rd, 2025 Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
January 2nd, 2025 Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference
-
December 10th, 2024 Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium
-
December 9th, 2024 Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor
-
February 4th, 2025 Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
February 3rd, 2025 Olema Oncology to Participate in Upcoming Investor Conferences
-
January 3rd, 2025 Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
January 2nd, 2025 Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference
-
December 10th, 2024 Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium
-
December 9th, 2024 Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor
Item 1 of 6